Comparison of efficacy of ipraglifrozine and high-dose metformin in patients with type 2 diabetes
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 05 Mar 2019
Price : $35 *
At a glance
- Drugs Ipragliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms COLOR
- 29 Aug 2018 Status changed from recruiting to active, no longer recruiting.
- 01 Apr 2015 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 01 Sep 2014 New trial record